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Abstract
Background: Measurement of health utilities is required for economic evaluations. Few studies have evaluated
health utilities for rare conditions; even fewer have incorporated disutility that may be experienced by caregivers.
This study aimed to (1) estimate health utilities for three rare conditions currently recommended for newborn
screening at the state or federal level, and (2) estimate the disutility, or spillover, experienced by parents of patients
diagnosed with a rare, heritable disorder.
Methods: A stated-preference survey using a time trade-off approach elicited health utilities for Krabbe disease,
phenylketonuria, and Pompe disease at varying stages (mild, moderate, severe) and onset of disease symptoms
(infancy, childhood, and adulthood). We recruited respondents from a nationally representative community sample
(n = 862). Respondents valued disease specific health states in three consecutive question frames: (1) adult health
state (> = 18 years of age), (2) child health state (< 18 years of age), and (3) as a parent of a child with a condition
(parent spillover state). Corresponding mean utilities were calculated for plausible disease states in adulthood and
childhood. Mean disutility was estimated for parental spillover. Predictors of utilities were evaluated using a
negative binomial regression model.
Results: More severe conditions and infant health states received lower estimated utility and greater estimated
disutility among parents. Conditions with the lowest estimated health utilities were severe infantile Pompe disease
(0.40, CI: 0.34–0.46) and infantile Krabbe disease (0.37, CI: 0.32–0.43). Disutility was evident for all conditions
evaluated (range: 0.07–0.19).
Conclusions: Rare childhood conditions are associated with substantial estimated losses in quality of life. Evidence
of disutility among parents further warrants the inclusion of spillover effects in cost-effectiveness analyses.
Continued research is needed to assess and measure the effects of childhood disease from a family perspective.
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Spillover, Health disutility, Family effects
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Background
Newborn screening has expanded rapidly over the last
two decades with the introduction of tandem mass spec-
trometry, advances in genetic identification, and policy ini-
tiatives to improve and align newborn screening resources
[1, 2]. Currently, 34 conditions are recommended for
screening by the Advisory Committee for Heritable Disor-
ders in Newborns and Children (ACHDNC) [3]. States
typically view these recommendations as a minimum set
of conditions for which to screen; many states screen for
more than 50 conditions [4].
Economic evaluations are conducted to better estimate
the implications of expanding newborn screening for
recommended disorders. Health utility estimates are
required as part of economic evaluation to quantify the
burden of disease and derive quality-adjusted life years
(QALYs), the outcome measure recommended for use in
cost-effectiveness analysis [5–7]. To date few studies
have elicited health utilities for conditions recommended
for newborn screening; utility estimates are necessary for
evaluating whether the averted morbidity and mortality
for patients identified through newborn screening are
worth the costs associated with earlier detection and
treatment of heritable disorders [8].
A growing body of evidence suggests that quality of
life effects included in economic evaluations should be
considered beyond the individual patient. Parents, family
members, and informal caregivers can be significantly
affected by the stress and caregiving responsibilities
related to a family member’s disease [9–13]. Few studies
have directly measured these ‘spillover’ effects. Among
studies that have, results vary depending on the disease
state, the relationship of a family member to the ill pa-
tient, and patient age [14]. Opportunities exist to more
comprehensively capture the burden of disease in eco-
nomic evaluation by considering the quality of life effects
on both patients and family members.
This study aimed to estimate health utilities to support
economic evaluations using a family perspective. We
used accepted health utility elicitation techniques to (1)
estimate health utilities at varying ages and stages of
disease from infancy to adulthood, and (2) estimate paren-
tal spillover effects for three rare conditions: Krabbe dis-
ease, phenylketonuria (PKU), and Pompe disease (Fig. 1).
These conditions share the substantial risk of death or
severe sequelae if not identified and treated close to
birth. Additionally, all conditions have either been rec-
ommended or nominated by the Advisory Committee
for Heritable Disorders in Newborns and Children
(ACHDNC) for screening [15–17]. Although Krabbe
disease is not currently included on the recommended
uniform screening panel endorsed by the ACHDNC, 4
states are currently screening for Krabbe disease with 6
other states in various stages of implementation [18].
Secondary objectives of this study aimed to evaluate dif-
ferences in health utility valuations based on respondent
confidence, predictors of health utility valuations, and
use of video health state descriptions.
Methods
We developed an online, stated-preference survey to
elicit health utilities using direct-valuation methods. The
time trade-off (TTO) approach asked respondents to
trade off a portion of their remaining life to avoid an
undesirable health state. The modified time trade off
approach utilized in this study has been used previously
to elicit utilities for childhood health states [19, 20] and
Fig. 1 Rare Disorder Descriptions
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family spillover [11]. Derived utility values are calculated
on a scale from (0) dead to (1) perfect health [21].
Study participants
We invited a nationally representative sample of adults
to participate in this study. This community sample was
drawn from a commercially available panel of US adults,
the GfK KnowledgePanel [22]. GfK recruits panel
members via random digit dialing and address-based
sampling. Members are compensated for their participa-
tion in the panel with personal home internet access. In
addition, we identified a convenience sample of adult
patients and parents experienced with PKU and mild-
hyperphe, a mild variant of PKU, to participate in the
survey. Further details regarding the experienced sample
recruitment and results can be found in the online ap-
pendix (Additional file 1).
Survey design and development
The survey included four sections: an eligibility screener,
TTO practice questions, TTO health state valuations,
and questions concerning current wellbeing and
socio-demographics. The screener collected information
regarding the respondent’s age, gender, and familiarity
with the three conditions. Hover-over text was provided
to describe the three conditions to identify community
members experienced with one of the three conditions.
Health state scenario descriptions for the TTO tasks
were developed in consultation with patients and medical
experts familiar with Krabbe, PKU, and Pompe disease.
Health states were based on a combination of attributes
including stage of disease (mild, moderate, or severe), age
of symptom onset (infancy, childhood, or adulthood),
adherence to therapy (low or high) and treatment. In total,
18 health states were developed for health utility elicit-
ation: 4 PKU, 6 Krabbe, 6 Pompe, and 2 enzyme replace-
ment therapy (ERT) treatment conditions. ERT is a
lifelong medical treatment for Pompe disease that slows
the progression of disease but is not curative.
Health state descriptions included physical, mental,
and emotional health domains as well as unique attri-
butes of each disorder like diet and medical care. In
addition to written health states, a graphic designer
created customized illustrations for a 20–30 s animated
video health state. Previous studies have shown that
many adults lack basic literacy and numeracy skills
required to understand written health states [23, 24];
videos offer an alternative medium to present health
states to reduce literacy barriers (Fig. 2). The complete
set of health state descriptions is available in the online
appendix (Additional file 1).
Fig. 2 Sample of a Health State Animation*
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TTO health state valuation questions
Respondents completed practice questions to cognitively
prepare for the TTO valuation task. After completion of
the practice questions, each respondent evaluated 6–9
parallel health states in three successive question frames:
(1) adult health state (> = 18 years of age), (2) child
health state (< 18 years of age), and (3) as a parent of a
child with a condition (parent spillover state). Frame 1
asked the respondent to imagine how she would feel if
she had the hypothetical condition (termed “Adult”
frame). The adult frame asked the respondent how
many years of her life she would trade off to avoid
having the condition herself. Frame 2 asked the re-
spondent to consider how her child would feel if her
child had the hypothetical condition (termed “Child
Patient” frame). The child patient frame question
asked the respondent how many years of her life she
would tradeoff to avoid her child from having the
condition. Frame 3 asked the respondent to imagine
how she would feel if her child had the hypothetical
condition (termed “Spillover” frame). The spillover
frame asked the respondent how many years of her
life she would trade to avoid her own pain and
suffering if her child had the condition (Fig. 3). Each
respondent received personalized information on
remaining life years based on the respondent’s age
and national estimates of life expectancy in the
United States [25]. After completion of the valuation
task, respondents were asked to assess their level of
confidence in their responses on a four-point scale:
(1) Very confident, (2) Somewhat confident, (3) Not
confident, and (4) They were total guesses.
Socio-demographic questions and metadata
GfK collects socio-demographic information on panel
members including race and ethnicity, household in-
come, education, marital status, employment status, and
internet access prior to panel participation. We also
collected metadata on health state video usage to evalu-
ate any differences in population characteristics and
utility ratings among users and non-users.
The survey instrument was tested and refined through
cognitive interviews (n = 31). The large number of
cognitive pretests reflects the complexity of the survey
and the valuation task.
Fig. 3 Sample of a Time Trade-Off Question
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Data collection
The survey was piloted online in February 2016 (n = 75).
The survey was administered between March and June
2016; 2132 individuals were invited to participate, of
which 862 individuals completed the survey (40% re-
sponse rate). Respondents were randomized to complete
one of five survey versions (Additional file 1). The sur-
vey took an average of 24 min to complete. All survey
instruments were approved by the University of Mich-
igan Medical School Institutional Review Board.
Statistical analysis
Statistical analyses were conducted using STATA v13
statistical software [26]. Primary analyses included sum-
mary statistics of the respondent population and mean
utility weights for plausible disease health states experi-
enced in adulthood and childhood (TTO Adult Frame
and Child Patient Frame). Non-parametric bootstrapping
procedures estimated standard errors and confidence
intervals around the means. Disutility weights, defined
as 1 minus the health state valued, were calculated for
the spillover health states (TTO Spillover Frame). In sec-
ondary analyses, respondents were dichotomized based
on their self-reported confidence in the valuation task.
“Confident” respondents included those who were (1)
confident or (2) somewhat confident in their valuations;
“Not confident” included those respondents who were
(3) not confident or responded their answers were (4)
total guesses. Summary statistics were re-calculated to
evaluate if utility weights differed depending on respond-
ent confidence.
Subsequent analyses included a negative binomial
regression model to assess relationships between time
trade-off amounts (in years) and respondent characteris-
tics. Responses were normalized by dividing the re-
spondent TTO amounts by the mean TTO amounts for
each health state. GEE models were used to adjust for
multiple responses per respondent. Evaluated character-
istics included video usage, age, sex, race and ethnicity,
household income, educational attainment, employment
status, marital status, and internet access prior to GfK
panel participation. Finally, summary statistics were
calculated for respondents using any health state video.
Fischer’s exact test evaluated differences in population
characteristics among video users and non-users.
Results
Respondent characteristics
Respondents (n = 862) ranged in age from 18 to 90 years
with a median age of 55. Respondent characteristics
were similar to the US general population with a few
exceptions, namely our sample was older and more
likely to be White and of non-Hispanic origin (74%)
[27]. Among respondents, 36% held a bachelor’s degree
or higher and 61% were married or living with a partner.
Approximately 56% of respondents reported being
employed at the time of survey participation while 24%
reported being retired (Table 1). None of the respon-
dents reported having or knowing someone with PKU,
Pompe disease, or Krabbe disease.
Health utility weights
Mean health utility weights were calculated for all child-
hood and adult conditions based on responses to the
Table 1 Respondent Characteristics











≥ 65 226 26.2
Race/Ethnicity
White, non-Hispanic 635 73.7
Black, non-Hispanic 79 9.2
Other, non-Hispanic 67 7.8
Hispanic 81 9.4
Education
< 12th Grade, no diploma 60 7.0
High School Graduate 251 29.1
Some college, Associate’s 242 28.1
Bachelor’s Degree or higher 309 35.9
Household Income
< $25,000 132 15.3
$25,000 - < $50,000 177 20.5
$50,000 - < 75,000 152 17.6
$75,000 - < $100,000 121 14.0
≥ $100,000 280 32.5
Refused 0 –
Respondent Confidence in Valuation Responsesa
Confident 717 83.2
Not Confident 139 16.1
Refused 6 0.7
aRespondents were dichotomized based on their self-reported confidence in
the valuation task. “Confident” respondents included those who were (1)
confident or (2) somewhat confident in their valuations; “Not Confident”
included respondents who answered (3) not confident or (4) they were
total guesses
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adult (frame 1) and child (frame 2) TTO questions
(Table 2; Fig. 4). Infantile-onset health states elicited the
lowest utility across all evaluated conditions. Severe in-
fantile Pompe disease (0.40, CI: 0.34–0.46) and infantile
advanced Krabbe disease (0.37, CI: 0.32–0.43) elicited
the lowest utilities. Conversely, the highest mean utilities
were calculated for milder health states in adulthood.
The highest utilities were estimated for adult early stage
Krabbe disease (0.81, CI: 0.76–0.85), adult mild Pompe
disease (0.85, CI: 0.81–0.89), and adult PKU with high
adherence to a low-protein diet (0.81, CI: 0.76–0.85).
This trend was also consistent for the enzyme replace-
ment therapy (ERT) treatment condition in which
assigned utilities were significantly lower for the child-
hood treatment states (0.48, CI: 0.42–0.53) compared to
the adult treatment states (0.67, CI: 0.62–0.72).
Parent disutility, or spillover, was calculated for all
childhood conditions (Table 3). Spillover estimated the
burden of disease on a parent of a child with one of the
specified conditions. The greater the spillover effect, the
greater the quality of life loss to the parent due to the
child’s condition. The greatest spillover disutility was
assigned to the infantile-onset advanced Krabbe condi-
tion (0.19, CI: 0.14–0.24). The lowest spillover disutility
was assigned to mild Pompe disease in childhood (0.07,
CI: 0.04–0.10). Mean spillover disutility assigned to the
PKU conditions, low and high adherence, were similar
(0.12 and 0.11 respectively).
Secondary analyses
Further analyses restricted approximately 16% of respon-
dents who expressed low confidence in their health state
valuations. Mean health utility results were similar
among the restricted sample compared to the full sam-
ple of respondents. Respondents with confidence in their
responses generally assigned lower health utility values
for more severe conditions in both adulthood and
childhood. These differences approached, but did not
reach, statistical significance (0.05) except for two
conditions, childhood severe Pompe disease (0.43, CI:
0.37–0.50) and the adult ERT treatment condition
(0.64, CI: 0.59–0.70; full results not shown).
Results of the regression analysis demonstrated that
few respondent characteristics were associated with time
trade off valuations. Marital status and employment
status were exceptions. Respondents who reported
separation from a partner or spouse and respondents
temporarily laid-off were less likely to trade off time at
the end of their life and therefore assigned higher util-
ities to described health states compared individuals
who were married or employed (Additional file 1).
Finally, descriptive statistics explored the frequency of
video use as well as respondent characteristics of video
viewers. Videos were most often accessed for health
states presented in the first question evaluated; at most
35% of respondents ‘clicked’ on the available video for
any given health state; 42% clicked on a video at least
once. Video ‘clicks’ progressively decreased as respon-
dents advanced through the survey. Among video users
and non-users, significant differences with regard to age
and home internet access were observed: video users
were more often over 60 years of age and reported hav-
ing home internet access prior to panel participation
(Additional file 1).
Discussion
This study estimated substantial quality of life losses as-
sociated with Pompe disease, PKU, and Krabbe disease.
Our results indicate that health utility and spillover ef-
fects vary by condition, age of symptom onset, and stage
of disease. Trends emerged in which more debilitating
conditions and infant onset conditions were associated
with lower ratings of utility and higher disutility among
Table 2 Health utilities derived from a community sample by
disease condition and age of patient
Health State Description Health Utility
N Mean 95% CIa
Krabbe Disease
Early Stage Illness, 6 months 166 0.469 0.409–0.532
Advanced Stage Illness, 6 months 167 0.374 0.316–0.430
Early Stage Illness, 8 years 168 0.548 0.490–0.606
Advanced Stage Illness,8 yr 168 0.440 0.380–0.500
Early Stage Illness,≥18 yr 167 0.806 0.757–0.847
Advanced Stage Illness,≥18 yr 167 0.554 0.497–0.612
Phenylketonuria
Less Adherent to Diet, 8 yr 170 0.564 0.506–0.623
More Adherent to Diet,8 yr 171 0.639 0.581–0.696
Less Adherent to Diet, ≥18 yr 171 0.679 0.628–0.730
More Adherent to Diet,≥18 yr 171 0.808 0.762–0.852
Pompe Disease
Severe Symptoms, 6 months 170 0.399 0.341–0.457
Mild Symptoms, 8 yr 171 0.799 0.750–0.844
Moderate Symptoms, 8 yr 169 0.414 0.355–0.475
Severe Symptoms, 8 yr 169 0.466 0.407–0.525
ERTb Treatment, 8 yr 170 0.475 0.417–0.534
Mild Symptoms, ≥18 yr 170 0.853 0.811–0.892
Moderate Symptoms, ≥18 yr 170 0.683 0.634–0.729
Severe Symptoms, ≥18 yr 171 0.536 0.480–0.594
ERTb Treatment, ≥18 yr 169 0.673 0.621–0.723
Disease health states listed ≥18 yr. of age are derived from Frame 1 TTO: Adult
health state questions
Disease health states listed for ages < 18 yr. are derived from Frame 2 TTO:
Child health state questions
aBootstrapped
bEnzyme replacement therapy
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parents. Our results corroborate existing research that
suggest infantile-onset conditions are more distressing
for parents and caregivers compared to conditions expe-
rienced in older children, adolescents, or adults [10].
Previous studies have reported health utilities for
Pompe disease and sequelae of PKU [28–33], but not
Krabbe disease. Studies have typically utilized indirect
elicitation methods. Our estimates for adult onset
Pompe disease and ERT are similar to other studies
[28–30]. In contrast, our health utility estimates for
childhood Pompe disease are higher than other esti-
mates [31]. For PKU, our results are consistent with
those reported from two studies valuing health related
quality of life for mild to moderate developmental delay
[32, 33]. Particularly among children, our results also
estimate quality of life losses for patient both adherent
and less-adherent to a low-protein diet. This is in con-
trast to other studies which have demonstrated that
with early detection of PKU and treatment, quality of
life among adolescents and adults is not different than
otherwise healthy individuals for studies using patients
as respondents [34–36]. This discrepancy is consistent
with research that indicates respondents who are inexperi-
enced with a health state (community sample), compared
with an experienced patient sample, may overestimate
quality of life losses at least for some conditions [37].
Fig. 4 Health Utilities by Disease Condition and Age of Symptom Experience or Onset
Table 3 Disutility estimates of parental spillover quantifying health-related quality of life losses due to childhood conditions
N Disutility Spillover decrement relative to child disutility
Mean 95% CIa Percent 95% CI
Krabbe Disease
Early Stage Illness, 6 months 167 0.152 0.110–0.195 32.4 26.9–36.7
Advanced Stage Illness, 6 months 167 0.190 0.141–0.238 50.8 44.6–55.3
Early Stage Illness, 8 years 168 0.136 0.096–0.177 24.8 19.6–29.2
Advanced Stage Illness, 8 yr 168 0.163 0.119–0.208 37.0 31.3–41.6
Phenylketonuria
Less Adherent to Diet, 8 yr 170 0.120 0.079–0.160 21.3 15.6–25.7
More Adherent to Diet, 8 yr 171 0.110 0.072–0.148 17.2 12.4–21.3
Pompe Disease
Severe Symptoms, 6 months 170 0.180 0.129–0.230 45.1 37.8–50.3
Mild Symptoms, 8 yr 171 0.072 0.042–0.103 9.0 5.6–12.2
Moderate Symptoms, 8 yr 169 0.162 0.116–0.208 39.1 32.7–43.8
Severe Symptoms, 8 yr 171 0.131 0.090–0.173 28.1 22.1–33.0
ERT Treatment, 8 yr 169 0.155 0.110–0.200 32.6 26.4–37.5
aBootstrapped
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When incorporating health utility weights into a cost-ef-
fectiveness analysis, it is important to consider the
respondent sample. Guidelines for cost-effectiveness ana-
lysis typically recommend health utility weights from a
community sample for resource allocation decisions [38]
and it is important to note that the selection of respond-
ent sample could influence the magnitude of weights.
This study is the first, to our knowledge, to elicit
spillover utilities using direct valuation methods for
these rare conditions. Parental spillover effects were de-
tected in all of the health conditions evaluated, and were
especially notable in severe early infantile and childhood
onset conditions. Among our sample, mean disutility or
parental spillover estimates ranged from 0.07 for mild
Pompe disease in childhood to 0.19 for severe early in-
fantile Krabbe disease. Other studies have reported mean
spillover effects within the ranges observed in our study
from 0.08 among experienced parents of children with
physical limitations [39], 0.10 among parents of children
with two rare congenital disorders [40], and mean spillover
of 0.26 among parents of children with a severe childhood
condition like cancer [11]. Our study is consistent with
findings from a previous study utilizing TTO methods in
which spillover effects between 0.08–0.27 were estimated
for a childhood condition requiring a restricted pro-
tein diet [41]. Our findings reiterate the importance
of including parental spillover effects into economic
evaluation as quality of life losses can be substantial.
In a previous study, we collected preferences for a false
positive newborn screening test result [41]. We found
that patients assigned a small but significant disutility of
0.003 (0.001 to 0.006) to the false positive newborn
screening experience and mean WTP to avoid this ex-
perience was $159 (95 to 246). While small at the indi-
vidual patient level, it is important to consider this value
when conducting cost-effectiveness analyses of newborn
screening, since false positive rates can vary substantially
across target conditions for a given population.
This study has some limitations. First, there are few
well-established methods for valuing child health util-
ities, especially for very young children [14, 42]. A recent
review highlighted the lack of evidence for judging the
use of direct valuation methods for child health [43].
More research is needed in this area to identify feasible
and reliable methods. Additionally, appropriate methods
for integrating parent and family spillover remains an
active area of discussion. Utilizing the direct elicitation
methods employed in this study, it is possible that par-
ental spillover effects are incorporated in child health
state valuations, which would result in double counting
of the quality of life losses among parents. This is espe-
cially possible in the early infantile-onset health states in
which it may be hardest for parents to separate the effect
of a disease on themselves versus their child. Further
understanding and development of methods to measure
and incorporate parental spillover can improve cost-ef-
fectiveness estimates of childhood interventions.
Second, some challenges are present due to the com-
plexity of the preference-based evaluation task. Wide
confidence intervals on many of our estimates indicate
substantial variability and uncertainty in measurements.
This is a recognized challenge in estimating quality of
life for pediatric conditions and is indicative of the
complexities of valuing child health for economic evalu-
ation [10, 44]. To mitigate against this complexity, we
attempted to find alternative formats to communicate
health state descriptions including videos to assist survey
respondents in their evaluation of the hypothetical
health states. While health utility ratings did not differ
based upon video usage, our results indicate that older
respondents were more likely to use the videos. Future
research should continue to explore a variety of methods
to communicate complicated health states to different
audiences through available web-based technology.
Third, consistent with conventional approaches to
utility elicitation, we did not specify the duration of time
spent in a specific health state. This could also have
added to the complexity of the questions as respondents
may have made assumptions for the duration of time
spent in a health state given the severe nature of some
of the health states.
Finally, we were limited in selecting an experienced (or
patient) sample of respondents due to the rare nature of
these conditions. Respondent valuations may not be repre-
sentative of all experienced adult patients and parents of
children with Pompe, PKU or Krabbe disease in the US.
As more states begin to screen for these rare diseases, par-
ticularly Pompe disease, state-based registries may become
more widely available to recruit experienced patients and
families to more fully understand the quality of life impli-
cations of these rare conditions and their treatment.
Conclusions
Our results indicate that estimated health utilities for
Krabbe disease, phenylketonuria, and Pompe disease vary
by condition, age of disease onset, and stage of childhood
disease; however, all conditions are associated with
substantial quality of life losses for children with these rare
conditions and their parents. Parental spillover effects
were observed across all childhood conditions in this
study and were especially notable among infantile-onset
and severe childhood conditions. Finally, quality of life
valuations reflect the burden of disease for both patients
and parents; our study further supports the inclusion of
parental spillover effects in economic evaluations to
fully assess the quality of life gains and losses related to
early detection and treatment of rare conditions in
pediatric populations.
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